"I’m a romantic and an optimist," Pfizer Inc. ’s new global head of R&D, Martin Mackay, told The RPM Report’s FDA/CMS Summit for Biopharma Executives in December. That much was clear from his upbeat assessment of the state of industry pipelines. And he didn’t stop there: "This is the golden age of drug discovery."
This is the golden age? The Food & Drug Administration approved just 17 new molecular entities in 2007, the lowest...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?